Even though it still awaits a substantial venture capital
investment for mass implementation, is Dr. Anita Goel’s Gene RADAR the future
of instant medical diagnosis for the world’s poor?
By: Ringo Bones
Even though her invention is a 500,000 US dollar XPRIZE Foundation Challenge winner, Dr. Anita Goel’s Gene RADAR still awaits substantial venture
capital investment for it to begin benefitting the medical diagnostic cost
burden to those over a billion people around the world who earns less than 2 US
dollars a day. Current reliable medical diagnostic tests to find out if whether
someone has HIV / AIDS, the dreaded Ebola virus or just your garden variety flu
used to take about a month for results, while the upcoming Gene RADAR was
recently demonstrated to accurately do the same feat within an hour using just
a drop of blood from the patient.
Dr. Anita Goel received a Ph.D. in physics from Harvard
University and is globally recognized for her pioneering research in nano-biophysics
particularly for the study of molecular mechanisms behind the reading and writing
information in DNA. Currently the
chairwoman and CEO of Nanobiosym Diagnostics, the Harvard-M.I.T. trained physicist
and physician now eagerly awaits for substantial venture capitalist investment to
make her Gene RADAR a commercially viable product that could benefit patients
who earn less than 2 US dollars a day.
The nanotechnology platform based Gene RADAR developed by
Nanobiosym Diagnostics is the first medical diagnostic tool of its kind that is
not only as accurate and reliable as existing medical diagnostic lab equipment
used in testing HIV / AIDS, Ebola and the flu, but can also produce reliable
results within an hour at a fraction of the costs of current similar medical diagnostic
tools. When deployed in Ebola hot-spots in the near future, Gene RADAR could
make the 2014 West African Ebola Pandemic a thing of the past.
No comments:
Post a Comment